Boston Therapeutics, Inc. - FORM 8-K - EX-23.1 - CONSENTS OF EXPERTS AND COUNSEL - January 27, 2011

Attached files

file filename
8-K - AMENDMENT TO CURRENT REPORT - NOVEMBER 18, 2010 - Boston Therapeutics, Inc.form8-k.htm
EX-99.2 - UNAUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2010 - Boston Therapeutics, Inc.ex-99_2.htm
EX-99.3 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2010 - Boston Therapeutics, Inc.ex-99_3.htm
EX-99.1 - UNAUDITED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2009 - Boston Therapeutics, Inc.ex-99_1.htm

 

 

 

McGladrey & Pullen, LLP

Certified Public Accountants

 

80 City Square

Boston, MA 02129-3742

O 617.912.9050 F 617.912.9051

www.mcgladrey.com

 

 

 

Consent of Independent Auditor

 

We consent to the incorporation by reference in the Registration Statement (No. 333-164785) on Form S-1/A of Avanyx Therapeutics, Inc. of our report dated January 26, 2011, relating to our audit of the financial statements of Boston Therapeutics, Inc. (a development stage company) as of December 31, 2009 and for the period from June 15, 2009 (date in inception) through December 31, 2009 (which report expresses an unqualified opinion and includes an explanatory paragraph relating to the substantial doubt about the Company’s ability to continue as a going concern) included in this Current Report on Form 8-K/A.

 

 

Boston, MA

January 27, 2011

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Boston Therapeutics, Inc. Reports